Baxter International Investors Invited to Lead Class Action Suit

Investors who acquired common stock of Baxter International, Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, may have the opportunity to serve as lead plaintiff in a class action lawsuit against the company. Robbins Geller Rudman & Dowd LLP has announced that those individuals have until December 15, 2025 to seek this designation in a case filed in the Northern District of Illinois.

The lawsuit, titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., alleges that the company and certain executives violated the Securities Exchange Act of 1934. The case claims that Baxter made misleading statements regarding its product, the Novum IQ Large Volume Pump (Novum LVP), which reportedly suffered from systemic defects. These defects led to significant malfunctions, including underinfusion and overinfusion of fluids, endangering patient safety.

Baxter was allegedly aware of multiple malfunctions and related injuries, yet failed to take adequate steps to rectify the situation. The lawsuit asserts that the company’s efforts to alert customers were insufficient, as the design flaws persisted and continued to pose risks to patients. Notably, on July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, stating it could not commit to a timeline for resuming these operations. This announcement reportedly caused Baxter’s stock price to drop by more than 22%.

Investors who suffered significant losses during the class period are encouraged to consider their options. The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during this timeframe to apply for the role of lead plaintiff. This individual would represent the interests of all class members and could select a law firm of their choice to handle the litigation.

For more information regarding the case or to express interest in becoming a lead plaintiff, investors can visit https://www.rgrdlaw.com/cases-baxter-international-class-action-lawsuit-bax.html or contact J.C. Sanchez or Jennifer N. Caringal of Robbins Geller via phone at 800-449-4900 or email at [email protected].

Robbins Geller Rudman & Dowd LLP is recognized as a leading law firm specializing in securities fraud and shareholder litigation. The firm has achieved notable success, recovering over $2.5 billion for investors in 2024 alone. With a team of approximately 200 attorneys across ten offices, Robbins Geller is among the largest plaintiffs’ firms globally and has secured some of the largest recoveries in securities class action history.

As the lawsuit progresses, it will be crucial for affected investors to remain informed and consider their participation in this legal action. The outcome may provide significant recourse for those who have experienced losses related to Baxter’s products.